X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5213) 5213
Publication (391) 391
Book Review (38) 38
Book Chapter (7) 7
Dissertation (6) 6
Conference Proceeding (5) 5
Magazine Article (1) 1
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atorvastatin (3581) 3581
humans (3300) 3300
index medicus (2751) 2751
male (2746) 2746
atorvastatin calcium (1981) 1981
female (1966) 1966
statins (1859) 1859
animals (1666) 1666
middle aged (1616) 1616
cholesterol (1193) 1193
pyrroles - pharmacology (1190) 1190
heptanoic acids - pharmacology (1187) 1187
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1130) 1130
aged (1126) 1126
pharmacology & pharmacy (1125) 1125
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (1114) 1114
simvastatin (1102) 1102
pyrroles - therapeutic use (1003) 1003
heptanoic acids - therapeutic use (1000) 1000
adult (859) 859
atherosclerosis (804) 804
rats (800) 800
cardiac & cardiovascular systems (774) 774
treatment outcome (680) 680
lipids (652) 652
peripheral vascular disease (611) 611
pravastatin (599) 599
inflammation (585) 585
mice (557) 557
endocrinology & metabolism (544) 544
cholesterol, ldl - blood (538) 538
risk factors (530) 530
anticholesteremic agents - therapeutic use (526) 526
pyrroles - administration & dosage (518) 518
dose-response relationship, drug (517) 517
hypercholesterolemia (517) 517
heptanoic acids - administration & dosage (516) 516
antilipemic agents (502) 502
metabolism (485) 485
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (483) 483
risk (471) 471
research (462) 462
expression (458) 458
statin (447) 447
hypercholesterolemia - drug therapy (443) 443
biochemistry & molecular biology (427) 427
coronary-heart-disease (418) 418
analysis (412) 412
oxidative stress (408) 408
c-reactive protein (407) 407
disease (406) 406
anticholesteremic agents - pharmacology (397) 397
rosuvastatin (391) 391
cholesterol - blood (378) 378
therapy (377) 377
cardiovascular-disease (373) 373
prevention (369) 369
diabetes (360) 360
cardiovascular disease (359) 359
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (354) 354
lipids - blood (353) 353
time factors (352) 352
drug therapy, combination (350) 350
care and treatment (346) 346
cells, cultured (344) 344
triglycerides - blood (344) 344
c-reactive protein - metabolism (339) 339
cardiovascular diseases (338) 338
disease models, animal (338) 338
double-blind method (332) 332
drug therapy (332) 332
coa reductase inhibitors (331) 331
drug interactions (327) 327
simvastatin - pharmacology (310) 310
rats, sprague-dawley (301) 301
statin therapy (293) 293
biomarkers - blood (292) 292
medicine, research & experimental (284) 284
pharmacokinetics (281) 281
prospective studies (280) 280
cholesterol, hdl - blood (279) 279
low density lipoproteins (279) 279
simvastatin - therapeutic use (279) 279
rats, wistar (276) 276
physiological aspects (275) 275
medicine, general & internal (270) 270
cardiovascular (269) 269
health aspects (266) 266
nutritional and metabolic diseases (263) 263
in-vitro (261) 261
medicine (256) 256
rosuvastatin calcium (252) 252
hyperlipidemias - drug therapy (249) 249
nitric-oxide synthase (245) 245
efficacy (244) 244
dyslipidemia (242) 242
mortality (241) 241
myocardial-infarction (239) 239
safety (239) 239
anticholesteremic agents - administration & dosage (236) 236
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5046) 5046
Chinese (57) 57
Russian (46) 46
Spanish (15) 15
German (12) 12
French (11) 11
Polish (9) 9
Korean (6) 6
Hungarian (5) 5
Japanese (5) 5
Turkish (4) 4
Persian (3) 3
Portuguese (3) 3
Czech (2) 2
Italian (2) 2
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, ISSN 0012-1797, 02/2017, Volume 66, Issue 2, pp. 347 - 357
MicroRNA-122 (miR-122) is abundant in the liver and involved in lipid homeostasis, but its relevance to the long-term risk of developing metabolic disorders is... 
MIR-122 | LIPID-METABOLISM | PLASMA | INSULIN-RESISTANCE | IN-VIVO | ENDOCRINOLOGY & METABOLISM | CARDIOVASCULAR-DISEASE | DENSITY-LIPOPROTEINS | OUTCOMES | PRIMATES | BRUNECK | Multivariate Analysis | Prevalence | Prospective Studies | Atorvastatin Calcium - pharmacology | Humans | Middle Aged | Glycoproteins - metabolism | Male | Metabolic Syndrome - metabolism | MicroRNAs - metabolism | Diabetes Mellitus, Type 2 - metabolism | Hepatocytes - metabolism | Serum Albumin, Human | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Oligonucleotides - pharmacology | Mass Spectrometry | Adult | Female | Real-Time Polymerase Chain Reaction | Atorvastatin Calcium - therapeutic use | Hepatocytes - drug effects | Metabolic Syndrome - epidemiology | Dyslipidemias - drug therapy | Insulin Resistance | Lipid Metabolism | Reverse Transcriptase Polymerase Chain Reaction | Obesity - metabolism | Blotting, Northern | Animals | Carrier Proteins - metabolism | Complement Factor H - metabolism | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lipoproteins, VLDL - metabolism | Obesity - epidemiology | MicroRNAs - drug effects | Dyslipidemias - metabolism | Aged | Mice | Serum Albumin - metabolism | Type 2 diabetes | MicroRNA | Analysis | Research | Metabolic syndrome X | Risk factors | Public health | Metabolism
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 2011, Volume 251, Issue 1, pp. 32 - 40
Consumption of beverages that contain fructose favors the increasing prevalence of metabolic syndrome alterations in humans, including non-alcoholic fatty... 
Fatty acid oxidation | NAFLD | ChREBP | NFκB | NFΚB | PPAR-ALPHA | KAPPA-B ACTIVATION | LIPID-METABOLISM | ELEMENT-BINDING PROTEIN | HYPERTRIGLYCERIDEMIA | DISEASE | FATTY LIVER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | TRANSCRIPTION FACTOR | UP-REGULATION | NF kappa B | CARDIOVASCULAR RISK | Hypertriglyceridemia - drug therapy | Metallothionein - metabolism | Liver - pathology | Phosphorylation | Hepatitis - enzymology | Liver - enzymology | Fatty Liver - pathology | Male | NF-kappa B - metabolism | I-kappa B Proteins - metabolism | Dietary Carbohydrates - metabolism | Fructose - metabolism | Necrosis | Hepatitis - prevention & control | Liver - drug effects | Hepatitis - genetics | Fatty Liver - enzymology | Inflammation Mediators - metabolism | Non-alcoholic Fatty Liver Disease | Lipid Metabolism - genetics | Fatty Acids - metabolism | Heptanoic Acids - pharmacology | Disease Models, Animal | Cyclic AMP-Dependent Protein Kinases - metabolism | Fatty Liver - genetics | Hepatitis - etiology | Oxidation-Reduction | Down-Regulation | Fatty Liver - prevention & control | Rats | Rats, Sprague-Dawley | Fructokinases - metabolism | Triglycerides - metabolism | Gene Expression Regulation - drug effects | Atorvastatin Calcium | Hypertriglyceridemia - enzymology | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hypertriglyceridemia - etiology | Lipid Metabolism - drug effects | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism | Fatty Liver - etiology | Liver diseases | Synthesis | Liver | Physiological aspects | Triglycerides | Beverages | Fatty acids | Fructose | Metallothionein | Antilipemic agents | Protein binding | Index Medicus | Enzymes | Transcription factors | Inflammation | Regulatory sequences | Metabolism | Dietary restrictions | reductase | Fatty liver | Molecular modelling | Hypertriglyceridemia | Atorvastatin | Fructokinase | Supplementation | steatosis | Metabolic disorders | PATIENTS | METALLOTHIONEIN | DIGESTIVE SYSTEM | RATS | TRIGLYCERIDES | HISTOLOGY | 60 APPLIED LIFE SCIENCES | FRUCTOSE | GLANDS | METABOLISM | ENZYMES | GENES | ESTERS | CHEMICAL REACTIONS | VERTEBRATES | LIPIDS | MAMMALS | HUMAN POPULATIONS | OXIDATION | TRANSCRIPTION FACTORS | ANIMALS | SACCHARIDES | CATABOLISM | RODENTS | ORGANIC COMPOUNDS | METALLOPROTEINS | INTAKE | ORGANIC ACIDS | POPULATIONS | SYMPTOMS | HEXOSES | KETONES | ORGANS | MONOSACCHARIDES | DISEASES | INGESTION | INFLAMMATION | LIVER | SYNTHESIS | CARBOXYLIC ACIDS | BEVERAGES | PROTEINS | BODY | PATHOLOGICAL CHANGES | CARBOHYDRATES | CONTROL | FOOD
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 92 - 99
The aim of the current study is to identify the human cytochrome P450 (P450) isoforms involved in the two oxidative steps in the bioactivation of clopidogrel... 
MECHANISM-BASED INHIBITION | ANTIAGGREGATING ACTIVITY | POLYMORPHISMS | TICLOPIDINE | PHARMACOKINETICS | HEALTHY-SUBJECTS | PHARMACOLOGY & PHARMACY | PRASUGREL | PHARMACODYNAMICS | MONOCLONAL-ANTIBODIES | ATORVASTATIN | Microsomes - metabolism | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Cytochrome P-450 Enzyme System - metabolism | Sulfaphenazole - pharmacology | Microsomes - drug effects | Cytochrome P-450 CYP3A - genetics | Cytochrome P-450 CYP1A2 - genetics | Antibodies - immunology | Omeprazole - pharmacology | Microsomes, Liver - enzymology | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Oxidoreductases, N-Demethylating - metabolism | Aryl Hydrocarbon Hydroxylases - immunology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Ticlopidine - analogs & derivatives | Oxidoreductases, N-Demethylating - immunology | Cytochrome P-450 CYP3A - metabolism | Cell Line, Tumor | Cytochrome P-450 Enzyme System - genetics | Theophylline - pharmacology | Kinetics | Cytochrome P-450 CYP2C9 | Theophylline - analogs & derivatives | Oxidoreductases, N-Demethylating - genetics | Glutathione - metabolism | Ketoconazole - pharmacology | Biotransformation - physiology | Cytochrome P-450 CYP1A2 Inhibitors | Microsomes, Liver - drug effects | Ticlopidine - metabolism | NADP - metabolism | Platelet Aggregation Inhibitors - metabolism | Cytochrome P-450 CYP3A - immunology | Cell Line | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Cytochrome P-450 CYP1A2 - immunology | Biocatalysis | Mephenytoin - analogs & derivatives | Cytochrome P-450 CYP1A2 - metabolism | Aryl Hydrocarbon Hydroxylases - metabolism | Mephenytoin - pharmacology | Antibodies - pharmacology | Cytochrome P-450 CYP3A Inhibitors | Cytochrome P-450 CYP2C19 | Clopidogrel | Cytochrome P-450 CYP2B6
Journal Article
Journal Article
Atherosclerosis, ISSN 0021-9150, 12/2017, Volume 267, pp. 116 - 126
Journal Article
Cell Death and Disease, ISSN 2041-4889, 02/2013, Volume 4, Issue 2, pp. e518 - e518
Journal Article
Atherosclerosis, ISSN 0021-9150, 2007, Volume 198, Issue 1, pp. 65 - 76
Abstract Objective HMG-CoA reductase inhibitors have been shown to upregulate GTP cyclohydrolase I (GTPCH-I), the key enzyme for tetrahydrobiopterin de novo... 
Cardiovascular | Nitric oxide synthase | Reactive oxygen species | HMG-CoA reductase inhibitors | Diabetes mellitus | Vascular biology | POSTTRANSCRIPTIONAL REGULATION | OXIDATIVE STRESS | CARDIAC & CARDIOVASCULAR SYSTEMS | NITRIC-OXIDE SYNTHASE | PROSTACYCLIN SYNTHASE | diabetes mellitus | vascular biology | ASCORBIC-ACID | ENDOTHELIAL PROGENITOR CELLS | NAD(P)H OXIDASE | MESSENGER-RNA | NITRATE TOLERANCE | reactive oxygen species | VASCULAR SUPEROXIDE PRODUCTION | PERIPHERAL VASCULAR DISEASE | nitric oxide synthase | Body Weight | Rats, Wistar | Oxidative Stress - physiology | Cytochrome P-450 Enzyme System - metabolism | Diabetes Mellitus, Type 1 - metabolism | Endothelium, Vascular - drug effects | Male | Endothelium, Vascular - enzymology | Phosphoproteins - metabolism | Biopterin - analogs & derivatives | Biopterin - metabolism | Stem Cells - enzymology | Microfilament Proteins - metabolism | Diabetes Mellitus, Experimental - metabolism | Intramolecular Oxidoreductases - metabolism | NADH, NADPH Oxidoreductases - metabolism | Heptanoic Acids - pharmacology | Disease Models, Animal | Diabetic Angiopathies - metabolism | Nitric Oxide Synthase Type III | Rats | Diabetic Angiopathies - drug therapy | Enzyme Activation - drug effects | GTP Cyclohydrolase - metabolism | Cell Adhesion Molecules - metabolism | NADPH Oxidase 1 | Tetrahydrofolate Dehydrogenase - metabolism | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Stem Cells - drug effects | Oxidative Stress - drug effects | Vasodilation - drug effects | Nitric Oxide Synthase Type II - metabolism | Diabetes | Antilipemic agents
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 03/2010, Volume 6, Issue 3, pp. 202 - 204
The role of nutrients and metabolism in cellular differentiation is poorly understood. Using RNAi screening, metabolic profiling and small-molecule probes, we... 
HEXOSE-6-PHOSPHATE DEHYDROGENASE | STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE | Nutrients | Biochemistry | Cellular biology | Metabolism | Ribonucleic acid--RNA | trichostatin A (TSA) | taurodeoxycholic acid (TUDCA) | fluvastatin | glycochenodeoxycholic acid | pravastatin | 3-phosphoglycerate | phosphoenol pyruvate (PEP) | atorvastatin | cyclosporin A (CsA)
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 12/2006, Volume 26, Issue 12, pp. 2716 - 2723
OBJECTIVE—Receptor for advanced glycation end products (AGEs) (RAGE) plays a central role in the process of plaque rupture in diabetic patients. Recently, it... 
Myeloperoxidase | RAGE | Metalloproteinases | Diabetes mellitus | Statins | ATHEROSCLEROTIC PLAQUES | MECHANISM | metalloproteinases | diabetes mellitus | myeloperoxidase | FACTOR-KAPPA-B | ATORVASTATIN | statins | INFLAMMATION | RECEPTOR RAGE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | PROGRESSION | GLYCATION END-PRODUCTS | Gene Expression Regulation, Enzymologic - drug effects | Diabetes Mellitus, Type 2 - genetics | Humans | Male | NF-kappa B - metabolism | Diabetes Mellitus, Type 2 - metabolism | Simvastatin - pharmacology | Carotid Stenosis - metabolism | Matrix Metalloproteinase 9 - metabolism | Cyclooxygenase 2 - genetics | Matrix Metalloproteinase 9 - genetics | Female | Membrane Proteins - metabolism | Receptor for Advanced Glycation End Products | Glycation End Products, Advanced - genetics | Macrophages - pathology | Gene Expression Regulation - genetics | Matrix Metalloproteinase 2 - metabolism | Membrane Proteins - genetics | Cells, Cultured | Carotid Stenosis - pathology | Gene Expression Regulation - drug effects | Matrix Metalloproteinase 2 - genetics | Macrophages - metabolism | NF-kappa B - genetics | Gene Expression Regulation, Enzymologic - genetics | Glycation End Products, Advanced - metabolism | Cyclooxygenase 2 - metabolism | Glucose - metabolism | Macrophages - drug effects | Peroxidase - genetics | Aged | Diabetes Mellitus, Type 2 - pathology | Receptors, Immunologic - genetics | Anticholesteremic Agents - pharmacology | Receptors, Immunologic - metabolism | Peroxidase - metabolism
Journal Article
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 06/2017, Volume 127, Issue 7, pp. 2855 - 2867
Epidemiologic and animal studies implicate overconsumption of fructose in the development of nonalcoholic fatty liver disease, but the molecular mechanisms... 
CHOLESTEROL-METABOLISM | MEDICINE, RESEARCH & EXPERIMENTAL | DIABETIC MICE | ENDOPLASMIC-RETICULUM-STRESS | FATTY LIVER-DISEASE | ER STRESS | INSULIN-RESISTANCE | SODIUM 4-PHENYLBUTYRATE PROTECTS | NONALCOHOLIC STEATOHEPATITIS | HEPATIC STEATOSIS | GROWTH-FACTOR 21 | Liver - pathology | Protein Binding - genetics | Cholesterol - genetics | Liver - injuries | Fructose - pharmacology | Protein Binding - drug effects | Sterol Regulatory Element Binding Protein 2 - genetics | Sterol Regulatory Element Binding Protein 2 - metabolism | Chemical and Drug Induced Liver Injury - pathology | Nuclear Proteins - genetics | Unfolded Protein Response - drug effects | Fructose - adverse effects | Unfolded Protein Response - genetics | Dietary Carbohydrates - pharmacology | Liver - metabolism | Nuclear Proteins - metabolism | Chemical and Drug Induced Liver Injury - genetics | Transcription Factors - genetics | Cholesterol - metabolism | Mice, Knockout | Transcription Factors - metabolism | Animals | Chemical and Drug Induced Liver Injury - metabolism | Mice | Dietary Carbohydrates - adverse effects | Care and treatment | Transcription factors | Liver diseases | Development and progression | Genetic aspects | Gene expression | Health aspects | Cholesterol metabolism | Adaptations | Pathogenesis | Lipids | Biosynthesis | CCAAT/enhancer-binding protein | Chaperones | Kinases | Proteins | Signal transduction | Ubiquitination | Fatty liver | Sterols | Protein folding | Rodents | Cell cycle | Sterol regulatory element-binding protein | Lipid metabolism | Lipogenesis | Hepatotoxicity | Adaptation | Metabolism | Fatty acids | Cholesterol | Fructose | Studies | Molecular modelling | Diet | Atorvastatin | Diabetes | Endoplasmic reticulum | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article